# US 2008/0188434 A1 · Role of FGF-20 in cancer diagnosis and treatment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0188434 A1
- Document ID: US20080188434A1
- Status: Published application
- Kind: A1
- Application number: 11/893,086
- Filed: 2007-08-13
- Published: 2008-08-07
- Earliest claimed: 2006-08-11
- Assignees: Cold Spring Harbor Laboratory
- Inventors: Scott Powers; Lars Zender; Rebecca A. Kohnz; Scott W. Lowe
- Web page: https://patentgrep.com/patent/US20080188434A1

## CPC

- C12N 5/0693: {Tumour cells; Cancer cells}
- A01K 67/0271: Chimeric vertebrates, e.g. comprising exogenous cells
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A01K 2217/058: due to expression of inhibitory nucleic acid, e.g. siRNA, antisense
- A01K 2227/105: Murine
- A01K 2267/0331: Animal model for proliferative diseases
- C12N 2501/119: Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/112: Disease subtyping, staging or classification
- C12Q 2600/136: Screening for pharmacological compounds
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention provides methods for diagnosing cancers in humans by detecting DNA amplifications in chromosomal region 8p22, which encompasses the FGF-20 gene and the EFHA2 gene. Also provided are cancer treatment methods using inhibitors of FGF-20 and EFHA2. The invention also provides methods for promoting successful regeneration of liver function. These methods can be used therapeutically to improve liver function following transplantation in both recipient and donor subjects.

## Claims

### Claim 1

A method of diagnosing cancer in a human patient, comprising:
providing a DNA sample from a tissue of the patient, and
detecting, in said DNA sample, amplification of a nucleic acid sequence in chromosomal region 8p22, wherein said amplification indicates that the patient has, or is susceptible of developing, cancer in said tissue.

### Claim 2

A method of selecting a human cancer patient for treatment with an inhibitor of FGF-20 or EFHA2, comprising:
providing a DNA sample from the cancer tissue of the patient, and
detecting, in said DNA sample, amplification of a nucleic acid sequence in chromosomal region 8p22, wherein said amplification indicates that the patient will be responsive to said treatment.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the nucleic acid sequence is from an FGF-20 or an EFHA2 gene.

### Claim 4 (depends on 3)

The method of claim 3, wherein the nucleic acid sequence is from an FGF-20 and an EFHA2 gene.

### Claim 6 (depends on 1, 2)

The method of any one of claim 1 or 2, wherein the tissue is liver, lung or breast tissue.

### Claim 7 (depends on 1, 2)

The method of any one of claim 1 or 2, wherein the tissue is colon tissue.

### Claim 8 (depends on 1, 2)

The method of any one of claim 1 or 2, wherein the cancer is Acute Myeloid Leukemia.

### Claim 9 (depends on 2)

The method of claim 2, wherein the inhibitor of FGF-20 is an anti-FGF-20 antibody or an antigen-binding fragment thereof, an anti-FGF-20 antisense molecule, or a siRNA against FGF-20.

### Claim 10

A method of inhibiting the growth of a basal subtype breast cancer cell, comprising contacting the cell with an anti-FGF-20 antibody or an antigen-binding fragment thereof, or a siRNA against FGF-20.

### Claim 11

A method of inhibiting the growth of a basal subtype breast cancer cell, comprising contacting the cell with an antisense nucleic acid that inhibits the expression of FGF-20.

### Claim 12

A mouse at least some of whose cells comprise a genome comprising a heterologous nucleic acid sequence comprising a EFHA2 coding sequence and an expression control sequence linked operatively thereto, wherein the mouse has cancer, or is more susceptible of developing cancer as compared to a control mouse not having said heterologous nucleic acid sequence.

### Claim 13 (depends on 12)

The mouse of claim 12, wherein the mouse is a chimeric mouse some or all of whose hepatocytes comprise said genome.

### Claim 14 (depends on 12)

The mouse of claim 12, wherein the mouse is a chimeric mouse some or all of whose breast cells comprise said genome.

### Claim 15 (depends on 12)

A method of identifying a molecule useful for treating cancer, comprising:
providing the mouse of claim 12, wherein the mouse has developed cancer, and
treating the mouse with a candidate molecule, wherein inhibition of the growth of said cancer or a regression of said cancer indicates the candidate molecule is useful for treating cancer.

### Claim 15

A method of promoting regeneration of the liver in a subject, comprising administering to the subject a composition comprising FGF-20 and a pharmaceutically acceptable carrier.

### Claim 16

A method of ameliorating a symptom associated with a liver transplant comprising administering to a subject a composition comprising FGF-20 and a pharmaceutically acceptable carrier.

### Claim 17

A method of improving liver function in a liver transplant recipient comprising administering to the recipient FGF-20 to enhance the replication of mature liver cells.

### Claim 18

A method of improving liver function in a liver transplant recipient comprising administering to the recipient FGF-20 to enhance the replication of hepatocytes surrounding the liver.

### Claim 19 (depends on 16, 17, 18)

The method of claims 16-18, wherein said recipient is in a post-replication phase of liver regeneration.

### Claim 20 (depends on 15)

The method of claim 15, wherein said subject is a liver donor.
